Feline Immunodeficiency Virus Vaccine

Creative Biolabs is a world leader in the field of vaccine development and can offer high-quality viral vaccines for use in prevention of viral infections. By consistently delivering the highest standards of quality, professionalism, and integrity, we want to become the partner of a choice for your requirements. Feline immunodeficiency virus is a lentivirus that affects cats worldwide. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services against feline immunodeficiency virus.

Feline Immunodeficiency Virus Vaccine - Creative Biolabs

Feline immunodeficiency virus (FIV) is a retrovirus of the genus Lentivirus that affects cats worldwide. The FIV genome is comprised of three main structural genes, gag, pol, and env, which encode internal structural proteins, viral enzymes and envelope glycoproteins, respectively. It has at least five subtypes (A-E) with subtypes A and B being most prevalent globally followed by subtype C. FIV is transmitted primarily through deep bite wounds and causes an AIDS-like illness in domestic cats, where the infected cat's saliva enters the other cat's tissues. Domestic cats infected with FIV develop a progressive immune dysfunction characterized by depletion of CD4+ T cells, eventually signs of cachexia, gingivitis-stomatitis, wasting and neuropathological disorders appear, together with an increased incidence of malignancy.

Inactivated FIV Vaccine

At present, the inactivated whole-virus vaccines have provided the most consistent efficacy against homologous FIV challenges. Conventional FIV vaccines have a unique advantage in that the viral antigens generally consist of closely related variants that develop in cell cultures, whereas molecular vaccine designs provide highly cloned viral antigens that are generally derived from a single variant. Due to the intrinsic diversity of variants in conventional vaccines, the immunity generated by these vaccines may be more expansive than that induced by molecular vaccines. Among these vaccines, a dual-subtype, whole-virus vaccine containing FIV subtype A (Petaluma) and subtype D (Shizuoka) viruses inactivated with formalin and combined with an adjuvant was proved the best combination, providing significant efficacy against homologous and heterologous in vivo-derived FIV challenges. The vaccine was shown to be moderately protective (82% of cats were protected) against subtype A FIV and 100% effectiveness against two different subtype B FIV strains.

Subunit Vaccines

A subunit vaccine with recombinant FIV surface glycoproteins was under development. This vaccine was constructed by recombinant SU from an FIV Zurich 2 (FIV Z2) strain and expressed by the baculovirus expression system adsorbed on aluminum hydroxyde. It was administered with Freund's adjuvant together with the recombinant nucleocapsid protein (protein NC) of rabies virus. Protein NC was described to act as an exogenous superantigen. After vaccination, the high detectable antibody response in cats was determined to the vaccine antigen. In conclusion, the results indicate that immunization with recombinant FIV SU in conjunction with appropriate adjuvants may lead to partial protection against FIV challenge infection.

DVA Vaccines

DNA-mediated immunization has emerged recently as a promising alternative approach to the development of viral vaccines. Thus, a DNA vaccine was composed of a defective mutant provirus of FIV with an in-frame deletion inpol (FIVΔRT) was tested for FIV. Cats vaccinated with plasmid DNA carrying FIV structural genes, including ENV and p10 gene, exhibited strong humoral immune responses. The polynucleotide molecule of the vaccine composition is preferably administered as part of an expression vector construct, such as a plasmid or a viral vector. Through a series of experimental tests and observations, it demonstrated that this DNA vaccination can elicit protection against FIV infection. Therefore, this DNA vaccine can be an option in FIV vaccine development.

Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against feline immunodeficiency virus. Our scientists are confident in offering the best services and products upon request!


All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.


Online Inquiry

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CONTACT US

USA

Tel:
Fax:
Email:
UK

Tel:
Email:
Germany

Tel:
Email:


Follow us on